Cost-utility analysis of edaravone dexborneol for acute ischemic stroke
10.12173/j.issn.1005-0698.202305025
- VernacularTitle:依达拉奉右莰醇治疗急性缺血性脑卒中的成本-效用分析
- Author:
Shasha ZHOU
1
;
Xiangfan CHEN
;
Xia CHEN
Author Information
1. 南通市第一人民医院药剂科(江苏南通 226000)
- Keywords:
Edaravone dexborneol;
Edaravone;
Acute ischemic stroke;
Decision tree model;
Cost-utility analysis
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(1):68-74
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of edaravone dexborneol versus edaravone alone combined with conventional therapy in patients with acute ischemic stroke(AIS).Methods From the perspective of the healthcare systems,a decision tree model was constructed using the data from the randomized double-blind comparative trial of edaravone dexborneol in the treatment of acute ischemic stroke(TASTE trial).Cost-utility analysis was used to evaluate the health benefits of edaravone dexborneol at 1 month and 5 years.The robustness of the results was tested by single factor sensitivity analysis and probability sensitivity analysis.Results For AIS patients,the 1-month incremental cost-utility ratio was 53 212.89 yuan/quality-adjusted life-year(QALY),and the 5-year incremental cost-utility ratio was 49 631.25 yuan/QALY,both of which were smaller than China's per capita GDP in 2022(85 698 yuan).Univariate sensitivity analysis showed that the change of NIHSS score in 2 groups of improved patients,the probability of improvement in 2 groups and the probability of deterioration in edaravone group were the most influential factors on the outcome of incremental cost effectiveness.The results of probabilistic sensitivity analysis showed that edaravone dexcborneol was more economical when WTP was 1 times China's per capita GDP in 2022.Conclusion Edaravon dexborneol is a more effective and economical treatment for acute ischemic stroke patients than edaravone alone.
